Eltrombopag and liver function in ITP patients
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how the drug eltrombopag affects the liver in people with primary ITP (immune thrombocytopenic purpura), a condition where the immune system destroys platelets. It aims to check if liver problems develop during treatment and who might be at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary ITP (immune thrombocytopenic purpura).
- You are currently taking or about to start eltrombopag as part of your treatment.
- Your liver function tests at the start of the study were normal.
- You may or may not have diabetes or fatty liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for people with ITP (low platelets) whose condition didn't improve after steroids. One group gets only eltrombopag (a platelet booster pill) and the other gets eltrombopag plus ripertamab (an experimental antibody). The goal is to see if the combination works better at raising platelet levels.
This study tests drugs called thrombopoietin agonists to help raise platelet levels in adults with ITP. It may help reduce bleeding risk and improve daily life.
This study tests a new combination of two medicines to help raise platelet counts in people with persistent or chronic immune thrombocytopenia (ITP) whose platelets are still low after standard treatments. The goal is to see if this combination works better and is safe.
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.